Exercise increases soluble vascular Endothelial Growth Factor Receptor-1 (sFlt-1) in circulation of healthy volunteers

Medical Science Monitor

Volumn 12, Issue 2, 2006, Pages

  Bailey, Amelia Purser ^a   Shparago, Megan ^a   Gu, Jian Wei ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Exercise; sFlt 1; VEGF

Indexed keywords

VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN EXPERIMENT; IMMOBILIZATION; MALE; NORMAL HUMAN; OXYGEN CONSUMPTION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; TASK PERFORMANCE; TREADMILL EXERCISE; VOLUNTEER;

ADULT; ATHEROSCLEROSIS; EXERCISE; EXERCISE TEST; FIBROBLAST GROWTH FACTOR 2; HUMANS; MALE; NEOPLASMS; RISK FACTORS; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 32044456959     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL: Actual causes of death in the United States, 2000, JAMA, 2004; 291: 1263-64
2. Booth FW, Gordon SE, Carlson CJ, Hamilton MT: Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol, 2000; 88: 774-87
3. Doll R: Epidemiological evidence of the effects of behavior and the environment on the risk of human cancer. Recent Results Cancer Res, 1998; 154: 3-21
4. Thune I, Furberg AS: Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med Sci Sports Exerc, 2001; 33: S530-S550
5. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS: Physical activity and the incidence of coronary heart disease. Annu Rev Public Health, 1987; 8: 253-87
6. Sacco RL, Benjamin EG, Broderick JP et al: American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk Factors. Stroke, 1997; 28: 1507-17
7. Matsakas A, Mougios V: Opposite effect of acute aerobic exercise on plasma endothelin levels in trained and untrained men. Med Sci Monit, 2004; 10(10): CR568-CR571
8. Maeda S, Tanabe T, Miyauchi T et al: Aerobic exercise training reduces plasma endothelin-1 concentration in older women. J Appl Physiol, 2003; 95: 336-41
9. Roberts CK, Barnard RJ: Effects of exercise and diet on chronic disease. J Appl Physiol, 2005; 98: 3-30
10. Giovanucci E: Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr, 2001; 131: 3109S-3120S
11. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst, 2000; 92: 1472-89
12. Chan JM, Stampfer MJ, Giovannucci E et al: Plasma insulin-like growth factor-1 and prostate cancer risk: a prospective study. Science, 1998; 279: 563-66
13. Hankinson SE, Willett WC, Colditz GA et al: Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet, 1998; 351: 1393-96
14. Ma J, Pollak M, Giovannucci E et al: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst, 1999; 91: 620-25
15. Ferrara N: The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS, 2005; 94: 209-31
16. O'Reilly MS, Shing Y, Chen C et al: Angiogenesis: a novel angiogenesis inhibitor that mediates the suppression of metastases by Lewis lung carcinoma. Cell, 1994; 79: 315-28
17. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nature Medicine, 1995; 1: 27-31
18. Hanahan DFJ: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996; 86: 353-64
19. O'Reilly MS, Boehm T, Shing Y et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 1997; 88: 277-85
20. Gu JW, Bailey AP, Sartin A et al: Ethanol stimulates tumor progression and expression of vascular endothelial growth factor in chick embryos. Cancer, 2005; 103: 422-31
21. Kendall RL, Thomas KA: Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA, 1993; 90: 10705-9
22. Kendall RL, Wang G, Thomas KA: Identification of a natural soluble form of the vascular endothelial growth factor receptor, Flt-1, and its heterodimerization with KDR. Biochem Biophys Res Commun, 1996; 226: 324-28
23. Chung NA, Lydakis C, Belgore F et al: Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart, 2003; 89: 1411-15
24. Felmeden DC, Spencer CG, Belgore FM et al: Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens, 2003; 16: 11-20
25. Blann AD, Belgore FM, McCollum CN et al: Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes. Clin Sci, 2002; 102: 187-94
26. Goldman CK, Kendall RL, Cabrera G et al: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA. 1998; 95: 8795-800
27. Mahasreshti PJ, Navarro JG, Kataram M et al.: Adenovirus-mediated soluble Flt-1 gene therapy for ovarian carcinoma. Clin Cancer Res, 2001; 7: 2057-66
28. Gu JW, Gadonski G, Wang J et al: Exercise increases endostatin in circulation of healthy volunteers. BMC Physiology, 2004; 4(1): 2
29. Hornig C, Behn T, Bartsch W et al: Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sFlt-1) by ELISA. J Immunol Methods, 1999; 226: 169-77
30. Ellestad MH: Stress testing protocol. In Stress Testing: Principles and Practice, edited by Ellestad MH. Philadelphia, PA: F. A Davis Company, 1996
31. Banks RE, Forbes MA, Searles J et al: Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod, 1998; 4: 377-86
32. Hornig C, Barleon B, Ahmad S et al: Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest, 2000; 80: 443-54
33. Maynard SE, Min JY, Merchan J et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest, 2003; 111: 649-58
34. Gerber HP, Condorelli F, Park J, Ferrara N: Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. J Biol Chem, 1997; 272: 23659-67
35. Sundberg CJ, Kaijesr L: Effects of graded restriction of perfusion on circulation and metabolism in the working leg; quantification of a human ischaemia model. Acta Physiol Scand, 1992; 146: 1-9
36. Gustafsson T, Puntschart A, Kaijser L et al: Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. Am J Physiol Heart Circ Physiol, 1999; 276: H679-H685
37. Richardson RS, Noyszewski EA, Kendrick KF et al: Myoglobin O2 desaturation during exercise. Evidence of limited O2 transport. J Clin Invest, 1995; 96: 1916-26
38. Clauss M: Functions of the VEGFR-1 (Flt-1) in the vasculature. Trends Cardiovasc Med, 1998; 8: 241-45
39. Ahmed A, Dunk C, Kniss D, Wilkes M: Role of VEGFR-1 (Flt-1) in mediating calcium-dependent nitric oxide release and limiting DNA synthesis in human trophoblast cells. Lab Invest, 1997; 76: 779-91
40. Gabrilovich DI, Chen HL, Girgis KR et al: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med., 1996; 2: 1096-103
41. Kim NH, Oh JH, Seo JA et al: Vascular endothelial growth factor (VEGF) and soluble VEGF receptor Flt-1 in diabetic nephropathy. Kidney International, 2005; 67: 167-77
42. Zhao Q, Egashira K, Inoue S et al: Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis. Circulation, 2002; 105: 1110-15
43. Tissot van Patot MC, Leadbetter G, Keyes LE et al: Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol, 2005; 98: 1626-29
44. Kraus RM, Stallings III HW, Yeager RC, Gavin TP: Circulating plasma VEGF response to exercise in sedentary and endurance-trained men. J Appl Physiol, 2004; 96: 1445-50